Sector News

Allergan announces changes to board leadership

October 27, 2016
Life sciences

Allergan plc has announced changes to leadership roles within its board of directors.

Effective today, Brenton L. Saunders has been elected Chairman of the Allergan’s Board of Directors replacing Paul Bisaro, who served as Executive Chairman since July 1, 2014. Bisaro will remain a member of the Allergan Board of Directors. In addition to the role of Chairman, Saunders will retain his current role as Chief Executive Officer and President. Also, effective today, Christopher Coughlin has been elected Lead Independent Director.

“In 2013, Actavis was a leading global generics company when we began our transformation into a branded leader by acquiring Warner Chilcott. We followed that by acquiring Forest Laboratories in 2014 and Allergan in 2015,” said Paul Bisaro. “With the sale of our Global Generics business to Teva in August 2016 and our Anda distribution business in October 2016, we have now completed the transformation to a global branded Growth Pharma company with operations in nearly 100 countries and annual sales of approximately $15 billion. With this transformation complete, this is the right time to transition leadership of the Allergan Board of Directors to Brent, who has led the company so ably since becoming CEO and President in July 2014.” Saunders has served as a member of Allergan’s Board of Directors and as Chief Executive Officer and President since July 2014. He was previously Chief Executive Officer and President of Forest and a member of the Board of Directors of Forest. He is currently a member of the Board of Trustees of the University of Pittsburgh, The Business Council and PhRMA.

“During his tenure with our company, Paul has provided impressive leadership to Allergan and its Board of Directors. His strategic vision led the way to our transformation. Paul’s wisdom, partnership and deep understanding of the biopharmaceutical industry have been invaluable to me as we transformed Allergan into a Growth Pharma leader, and I am happy that our Board will continue to benefit from his expertise,” said Brent Saunders. “I would like to express my thanks to Paul, the Nominating and Corporate Governance Committee and the full Allergan Board of Directors for their continuing confidence and support.” Bisaro served as Executive Chairman of Allergan’s Board of Directors since July 2014. He previously served as our President and Chief Executive Officer and as Chairman of our Board of Directors beginning October 2013; prior to serving as Chairman he served on the Board of Directors beginning September 2007. Bisaro currently serves on the Boards of Directors of Zimmer Biomet Holdings, Inc. and Zoetis, Inc. and on the Board of Visitors of the Catholic University of America’s Columbus School of Law.

“With his depth of experience in biopharmaceuticals, his demonstrated skill in managing companies before, during and after significant corporate transformations, and his extensive service on public company boards, Chris Coughlin is well suited to serve as Allergan’s Lead Independent Director,” said Bisaro. “I would also like to thank Cathy Klema, who has served as our Lead Independent Director since 2014 and has been active in our ongoing dialogue with shareholders.” Klema remains a member of the board. Coughlin is currently a member of Allergan’s Compensation Committee and the Nominating and Corporate Governance Committee. In 2015, Coughlin was recognized by National Association of Corporate Directors (NACD) as Director of the Year. He joined the Allergan board in July 2014 after serving as a member of the Board of Directors of Forest since 2011. Coughlin currently serves as the Chairman of the Board of Dun & Bradstreet. He also serves on the Board of Directors of Alexion Pharmaceuticals and Hologic, Inc.

Source: Allergan plc

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.